Under the Paperwan

MANUSCO DE LA PROPERTA DEL PROPERTA DE LA PROPERTA DE LA PROPERTA DEL PROPERTA DE LA PROPERTA DEL PROPERTA DE LA PROPERTA DE LA PROPERTA DE LA PROPERTA DEL PROPERTA DE LA PROPERTA DEL PROPERTA DE LA PROPERTA DEL PROPERTA DE LA PROPERTA DE LA PROPERTA DE LA PROPERTA DE LA

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Linder the Paperwork Reduction Act of 1995, no persons are required to respond to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

valid OMB coriud number.
10/808,699
March 24, 2004
Marian Nakada
1644
CEN 5017USNP

····	T	U.S. Patent Document				
Examiner Initials	Cite No.1		nd Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
MH		2003/0027161	A1	Bejanin et al	02-06-2003	
	ļ				ļ	
	ļ				ļ	
						
			 	•		
	 				1	
					- 	
			<u> </u>	FIGN PATENT DOCUMENTS		

FOREIGN PATENT DOCUMENTS Foreign Patent Document Date of Publication Pages, Columns, Lines, of Cited Document where relevant Name of Patentee or Examiner Cite mm-dd-yyyy passages or relevant T° **Applicant of Cited Document** figures appear Initials Number⁴ No.1

Examiner	/Wahan Maddad/	Date	05/00/0005
Signature	/Maher Haddad/	Considered	06/22/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. s Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a waller OMB control of the contro

Under the Paperwork Reduction Act of 1995, no persons are required to respond to Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

Valid OMB Control number.
10/808,699
MARCH 24, 2004
MARIAN NAKADA
1644
CEN5017USNP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
МН		ZUCKER, "Tumor Cell-Stormal Cell Interactions in Cancer," DEPT. OF VETERAN AFFAIRS, 2004, 3 pages, USA.	
МН		ZUCKER ET AL, "Extracellular matrix metalloproteinase inducer (EMMPRIN) facilitates tumor angiogenesis," AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, 1998, page 41, Vol. 39.	
MH		SAMESHIMA ET AL, "Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts," Cancer lett., 2000, pp 177-184, vol. 157, No. 2.	l
MH		ZUCKER ET AL, "Tumorigenic Potential of Extracellular Matrix Metalloproteinase Inducer," AMERICAN JOURNAL OF PATHOLOGY, 2001, pp 1921-1928, Vol. 158, No. 6, American Society for Investigative Pathology.	<u>. </u>
MH		LOOKSMART, "Emmprin – Its Role in Tumor Angiogenesis and Metastasis," Life Sciences and Biotechnology, 2001, Merton Allen Association and Gale Group.	
		·	
			

Examiner	/Maher Haddad/	Date 0	5/22/2006
Signature	· ·	Considered V	,,

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 3

and not considered. Include copy of this form with next communication to applicant.

a concessi of anomicason areas it aspects a	TER OND CONDUCTION
Application Number	10/808,699
Filing Date	MARCH 25, 2004
First Named Inventor	NAKADA
Group Art Unit	5898
Examiner Name	HADDAD, MAHER M
Attorney Docket Number	CEN 5017USNP

				U.S. PATENT DOCUMENTS	<u> </u>	
Examiner Initials	Cite	U.S. Patent Do	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
	140.		- 		11111-00-77777	
						
			_	•		
		<u> </u>				
	<u> </u>		-	$\overline{}$		
	ļ		ــا ا			
	├				 	
	<u> </u>				_	
		<u> </u>	EODE	GN PATENT DOCUMENTS		1

				FORE	GN PATENT DOCUMENTS			
Examiner Initials	Cite No.1	Foreign	Patent Docu	ment	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
		Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	™
					\gg			
				_				

Examiner Signature	/Maher Haddad/	Date Considered 07/10/2006
*EXAMINER: I	nitial if reference considered, whether or not citation is i	n conformance with MPEP 609. Draw line through citation if not in conformance

1 Unique citation designation number, 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. s Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. • Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number. Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

a conection of thiormation unless it displays a valid CMB control humber.					
10/808,699					
MARCH 24, 2004					
NAKADA					
5898					
HADDAD, MAHER M					
CEN 5017USNP					

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
MH		BIWAS ETA L, "The Human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily." CANCER RES., 1995, pp 434-439, Vol. 55.	
MH		COUSSENS ET AL, "Matrix metalloproteinase inhibitors and cancer: trials and tribulations." SCIENCE, 2002, pp 2387-2392, VOL. 295.	
МН		DERYUGINA ET AL, "Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis." CANCER RES., 2002, pp 580-588, Vol. 62.	
MH		ELLIS ET AL, "Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor." CANCER RES., 1989, pp 3385-3391, VOL. 49.	
MH		FOLKMAN ET AL, "Angiogenesis in cancer, vascular, rheumatoid and other disease," NAT MED, 1995, pp 27-31, Vol. 1.	
МН		GUO ET AL, "Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells." J. BIOL CHEM, 1997, pp 24-27, VOL. 272.	
MH		HESLOP ET AL, "Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1." Lancet, 1995, pp 805-806, VOL. 346.	
МН		JAVADPOUR ET AL, "Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer – an update," EUR UROL, 1992, pp Suppl 1:1-4, Vol. 21.	
МН		KATAOKA ET AL, "Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collaagenase, stromelysin, and 72-kDa gelantinase." CANCER RES, 1993, pp 3154-3158, Vol. 53.	
MH		KLAGSBRUN ET AL, "Molecular angiogenesis," CHEM BIOL, 1999, R217-24, Vol. 6.	
MH		KOCH ET AL, "T cell activation-associated epitopess of C147 in regulation of the T cell response and their definition by antibody affinity and antigen density." INTERNAT. IMMUNOL., 1999, pp 777-786, Vol. 11.	
МН		MURAOKA ET AL, "Enhanced expression of a tumor-cell-derived collagenase- stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers," INT J CANCER, 1993, pp 19-26, Vol. 55.	
МН		POLETTE ET AL, "Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers," J HISTOCHEM CYTOCHEM, 1997, pp 703-709, Vol. 45.	
МН		SAMESHIMA E AL, "Expression of EMMPRIN (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas," INT J CANCER, 2000a, pp 21-27, Vol. 88.	
MH		SAMESHIMA ET AL, 'Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts." CANCER LETT, 2000b, pp 177-184, Vol. 157.	
МН		SOUNNI ET AL, "MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression," FASEB J, 2002, pp 5550564, Vol. 16.	
MH		STAFFLER ET AL, "Selective inhibition of T cell activation via CD 147 through novel	

	modulation of lipid rafts," J. IMMUNOL., 2003, pp 1707-1714, Vol. 171.	
МН	TANG ET AL, "Tumor-stroma interaction: Positive feedback of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN," MOL. CANCER RES., 2004, pp 73-80, VOL. 2.	- -
	ZUCKER ET AL, "Tumorigenic potential of extracellular matrix metallepreteinase inducer," AM J PATHOL., 2001, pp 1921-1928, Vol. 158.	
	US2003/0027161 (Bejanin et al) - 9 FEDRUARY 2009 (06.92.2003), see-paragraph	
	TUCKER S. "Turnor cell-stormal cell interactions in cancer. Grant application from the Department of Veterans Affairs, 24 August 2000 (24 08 2000)	
	LOOKSMART, EMMPRIN: its role in tumor angiogenesis and metastasis. 2001, page 1.	
	ZUCKER ET AL. Extracellular matrix metalloproteinase inducer (EMMPRIM) facilitates tumor angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting. (March 1998), Vol. 99, pp 41.	
	SAMESHIMA et al. Glioma cell extracellular matrix metallepreteinase induser (EMMPRIM) (CD147) stimulates production of membrane-type matrix metallepreteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett. 1 September 2000 (01.09.2000) Vel. 157, No. 2, pp 177-184.	
	ZUCKER ET AL, "Tumorigenic potential of extracellular matrix metallopreteinase induser. Am. J. Pathol. 2001, Vol. 150, No. 0, pp 1921-1928.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

/Maher Haddad/

Examiner Signature

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Date Considered

07/10/2006

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Page 1 of 1

Application Number	10/808,699
Filing Date	MARCH 25, 2004
First Named Inventor	NAKADA
Group Art Unit	5898
Examiner Name	HADDAD, MAHER
	<u> </u>
Attomey Docket Number	CEN5017USNP

		U.S. PA	TENT DOCUMENTS		
			U.S. Patent Docur		Danie Calina in Llane
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Unes, where relevant passages or relevant figures appear
					"
					74,
			NATELE BOOKINGS		

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, where relevant passages Foreign Patent Document Name of Patentee or Examiner Initials Cite or relevant figures Applicant of Cited Document Office³ Number⁴ KindCode⁵ appear OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published Cite No.1 T2 Examiner Initials* See International Search Report 7 077/3004/00101 dated 20 December 2004 MH

Examiner		Date	07/10/0006	
Signature	/Maher Haddad/	Considered	07/10/2006	